Evolution of Drug Survival with Biological Agents and Apremilast Between 2012 and 2018 in Psoriasis Patients from the PsoBioTeq Cohort.

Drug survival reflects treatment effectiveness and safety in real life. There is limited data on the variation of drug survival with the availability of additional biological (bDMARDs) or synthetic (sDMARDs) systemic treatments. We aimed to determine whether the increasing number of available systemic treatment in psoriasis over time affects drug survival. We used the Psobioteq cohort, a French prospective observational cohort enrolling patients with moderate to severe psoriasis. All patients initiating a first bDMARD or sDMARD were included. The primary outcome was the comparison of the drug survival over time. A multivariate cox proportional hazard ratio model was computed. There were 1,866 patients included, 739 females (39%) with a median age of 47 years. In multivariate Cox model, no association was found between the calendar year of initiation and drug survival (HR overlapping from 0.80 (0.42-1.52) to 1.17 (0.64-2.17), p=0.633). In conclusion, drug survival in psoriasis is not affected by the year of initiation.